Company Overview
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.11.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +1,044.09% |
| 6 Months: | +62.85% |
| 3 Months: | +96.33% |
| 1 Month: | +24.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANRO Alto Neuroscience, Inc. R3KPHARMA | 35.81 | -15.44 | $1.41B | 0.00% | -38.28% | -49.17% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -7.20M | -9.12M | -9.72M | -14.39M | -18.34M | -18.89M | -15.68M | -18.68M | -14.95M | -27.14M |
| Net Income | -7.28M | -8.66M | -9.14M | -13.42M | -16.03M | -16.78M | -15.17M | -17.71M | -14.18M | -26.24M |
| Diluted EPS | -1.97 | -2.33 | -2.44 | -0.76 | -0.60 | -0.62 | -0.56 | -0.65 | -0.52 | -0.80 |
| R&D Expense | 5.61M | 7.07M | 7.97M | 9.95M | 13.18M | 13.06M | 9.97M | 13.12M | 10.53M | 20.29M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 27.45M | 37.81M | 68.61M | 66.36M |
| Operating Income | - | -27.45M | -37.81M | -68.61M | -66.36M |
| EBITDA | - | -27.37M | -34.56M | -59.55M | -60.11M |
| Interest Expense | - | 0 | 1.37M | 1.38M | 2.47M |
| Pretax Income | - | -27.71M | -36.30M | -61.43M | -63.24M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -27.71M | -36.30M | -61.43M | -63.24M |
| Diluted EPS | - | -2.13 | -1.42 | -2.50 | -2.19 |
| R&D Expense | - | - | 30.29M | 47.00M | 45.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 50.85M | 86.63M | 177.54M | 184.69M |
| Current Assets | - | 49.22M | 85.39M | 169.34M | 177.72M |
| Cash & Equivalents | - | 48.34M | 82.55M | 168.23M | 176.48M |
| Inventory | - | - | - | - | - |
| Receivables | 1.50M | 333.00K | - | - | - |
| Total Liabilities | - | 89.26M | 158.30M | 26.08M | 33.55M |
| Current Liabilities | - | 5.56M | 5.61M | 10.01M | 11.32M |
| Long Term Debt | - | 9.46M | 9.86M | 11.56M | 18.40M |
| Total Debt | - | 9.75M | 9.99M | 16.94M | 23.96M |
| Total Equity | - | -38.41M | -71.67M | 151.46M | 151.14M |
| Shares Outstanding | - | 25.57M | 25.57M | 26.99M | 31.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -20.39M | -33.45M | -47.42M | -51.77M |
| Investing Cash Flow | - | -732.00K | -470.00K | -2.08M | -24.00K |
| Financing Cash Flow | - | 43.79M | 68.13M | 135.69M | 60.08M |
| Capital Expenditure | - | -732.00K | -470.00K | -2.08M | -24.00K |
| Free Cash Flow | - | -21.13M | -33.92M | -49.50M | -51.79M |
| Net Change in Cash | - | 22.66M | 34.21M | 86.19M | 8.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 72.2% | 50.7% | -40.6% | -41.8% |
| ROCE % | - | -60.6% | -46.7% | -41.0% | -38.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Alpha Wave Global, LP | 9.45% | 3.71M | $112.23M |
| 2 | Commodore Capital Lp | 6.94% | 2.72M | $82.43M |
| 3 | Blackrock Inc. | 5.40% | 2.12M | $64.20M |
| 4 | Perceptive Advisors Llc | 4.10% | 1.61M | $48.73M |
| 5 | Adage Capital Partners GP L.L.C. | 4.08% | 1.60M | $48.43M |
| 6 | Vanguard Capital Management LLC | 3.54% | 1.39M | $42.06M |
| 7 | Spruce Street Capital LP | 3.45% | 1.35M | $40.96M |
| 8 | Vivo Capital, LLC | 3.08% | 1.21M | $36.59M |
| 9 | Franklin Resources, Inc. | 2.58% | 1.01M | $30.67M |
| 10 | Armistice Capital, LLC | 2.20% | 864.00K | $26.15M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANRO
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
MOUNTAIN VIEW, Calif., August 27, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to pre…
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0.65. See our latest analysis for Alto Ne…
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with basic loss per share from continuing op…
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans
Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last 12 months, Alto Neuroscience has returne…
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
MOUNTAIN VIEW, Calif., July 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective tr…
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list. On June 15, ALTO highlighted the publication in Nature Medici…
ANRO — Frequently Asked Questions
What is the current share price of Alto Neuroscience, Inc. (ANRO)?
As of 2026-09-19 21:16 PDT, Alto Neuroscience, Inc. (ANRO) trades at $35.81 on NYSE. Its 52-week range is $3.12 to $36.64.
What is the market capitalisation of ANRO?
Alto Neuroscience, Inc. (ANRO) has a market capitalisation of $1.41B on NYSE.
What is the P/E ratio of ANRO?
ANRO trades at a trailing price-to-earnings (P/E) ratio of -15.44. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.45.
What is the return on equity (ROE) of ANRO?
ANRO has a return on equity (ROE) of -49.17%. Its return on capital employed (ROCE) is -38.28%.
Is ANRO a good stock to buy?
This page provides a data-driven analysis of Alto Neuroscience, Inc. (ANRO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.